Zafgen (NASDAQ: ZFGN) is creating first-in-class small molecules for a novel target with the potential to address the global obesity epidemic. Clinical trials of the company’s lead program have demonstrated unsurpassed efficacy in weight loss, with additional benefits in key cardiovascular metrics. Zafgen completed a successful upsized $110M IPO at the top of its price range in June 2014.

Headquarters Boston, MA
Pipeline Phase 2/3 programs advancing in 3 obesity-related indications